Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital

Niagen Bioscience (NASDAQ:NAGE) was upgraded by investment analysts at Freedom Capital to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

NAGE has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. Wall Street Zen lowered shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Canaccord Genuity Group cut their price objective on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $10.50.

Niagen Bioscience Stock Down 2.3%

Shares of Niagen Bioscience stock opened at $3.37 on Monday. The company has a market cap of $268.39 million, a PE ratio of 16.05 and a beta of 2.09. The business has a 50 day moving average of $3.70 and a 200 day moving average of $4.79. Niagen Bioscience has a 52 week low of $3.17 and a 52 week high of $12.41.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%. The business had revenue of $31.47 million for the quarter. On average, research analysts anticipate that Niagen Bioscience will post 0.22 earnings per share for the current year.

Institutional Trading of Niagen Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. bought a new stake in Niagen Bioscience during the third quarter worth about $3,678,000. Vanguard Group Inc. purchased a new position in shares of Niagen Bioscience during the third quarter valued at approximately $37,522,000. Ameritas Investment Partners Inc. purchased a new position in shares of Niagen Bioscience during the third quarter valued at approximately $45,000. Intech Investment Management LLC bought a new stake in shares of Niagen Bioscience in the 3rd quarter worth approximately $202,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Niagen Bioscience in the 3rd quarter worth approximately $48,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.